Skip to main content
Premium Trial:

Request an Annual Quote

Lundbeck to Use Cogenics' Genotyping Platform in Phase I Trials

NEW YORK (GenomeWeb News) – Cogenics said today that it will provide the Danish pharmaceutical company H. Lundbeck with genotyping services to support clinical drug studies.
 
Under the agreement, the Clinical Data subsidiary will conduct genotyping in its labs in Morrisville, NC, and in Bernried, Germany, for Lundbeck’s Phase I clinical trials. Cogenics said the period of the agreement is open-ended and that the companies plan to collaborate on other projects in the future.
 
Lundbeck is focused on developing and marketing drugs for treating psychiatric and neurological disorders.
 
Financial terms of the agreement were not released.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.